Name: Abakast L Tablet Naive Patient Of Hiv-1
SKU: 2738
Availability: InStock

Description

Abakast-L, a combination of Abacavir (600 mg) and Lamivudine (300 mg), serves as an antiviral medication aimed at preventing HIV-1 and HIV-2 infections. It operates primarily by inhibiting the reverse transcriptase enzyme, essential for viral replication. Administered orally, Abakast-L terminates the chain reaction in the viral replication cycle, thereby hindering the progression of HIV.

Administration:

Abakast-L is taken orally, with a bioavailability of approximately 83%. Both Abacavir and Lamivudine exhibit mean to maximum serum concentrations within an hour of ingestion. Food intake does not significantly affect absorption. The drug effectively penetrates the cerebrospinal fluid, with a CSF to plasma AUC ratio ranging from 30-44%. Metabolism occurs mainly in the liver, with less than 2% of the dose excreted unchanged. Lamivudine’s mean clearance is approximately 0.32 L/kg/h, with renal clearance contributing to about 70%.

Dosages:

For adults (≥12 years), the recommended dosage is 600 mg once daily. Children under two years receive dosages based on weight (4 mg/kg twice daily). Those weighing 30 kg should take 300 mg twice daily.

Elimination:

The half-life of Abakast-L is around 1.5 hours, and elimination primarily occurs through urinary excretion of metabolites. Approximately 83% of the dose is excreted as a combination of metabolites and unchanged drug, with the remainder eliminated in the feces. Lamivudine’s half-life is extended, lasting around 10 hours in blood lymphocytes.

Side Effects:

Hypersensitivity reactions, occasionally fatal, may occur. Lamivudine use can lead to opportunistic infections and complications related to HIV infection. Symptoms indicating multi-organ involvement, fever, rashes, nausea, vomiting, diarrhea, fatigue, and paresthesia may manifest. Respiratory symptoms like sore throat or cough are possible. Hypersensitivity symptoms are more likely within the first six weeks of Abacavir treatment. Additional side effects may occur; consult your healthcare provider for updates.

Availability:

Abakast-L is accessible in various countries, including South East Asia, South America, Eastern Europe, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Macedonia, Poland, Republic of Kosovo, Republic of Moldova, Romania, Russia, Serbia, Slovak Republic, Slovenia, Malaysia, Indonesia, Philippines, Venezuela, Korea, and more. For specific availability, consult local healthcare providers.